Journal
PRESSE MEDICALE
Volume 48, Issue 10, Pages 1131-1137Publisher
MASSON EDITEUR
DOI: 10.1016/j.lpm.2019.04.005
Keywords
-
Categories
Ask authors/readers for more resources
Managing endocrine resistance and resistance to endocrine therapy for ER+ HER2- breast cancer with the CDK 4/6 inhibitors in the metastatic setting. New antibodies drug conjugates for HER2+ and TNBC. Targeting DNA damage and synthetic lethality strategies with PARP inhibitors for breast cancer patients harboring BRCA mutation. Immunotherapies in 1st line metastatic setting of TNBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available